Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
0.8882
+0.0113 (1.29%)
Sep 15, 2025, 4:00 PM EDT - Market closed
Sutro Biopharma Employees
Sutro Biopharma had 310 employees as of December 31, 2024. The number of employees increased by 8 or 2.65% compared to the previous year.
Employees
310
Change (1Y)
8
Growth (1Y)
2.65%
Revenue / Employee
$337,010
Profits / Employee
-$673,216
Market Cap
75.30M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 310 | 8 | 2.65% |
| Dec 31, 2023 | 302 | 24 | 8.63% |
| Dec 31, 2022 | 278 | 54 | 24.11% |
| Dec 31, 2021 | 224 | 33 | 17.28% |
| Dec 31, 2020 | 191 | 23 | 13.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
STRO News
- 5 weeks ago - Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - Sutro Biopharma to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 - GlobeNewsWire
- 6 months ago - Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - GlobeNewsWire
- 6 months ago - Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline - Benzinga
- 6 months ago - Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline - GlobeNewsWire